Melanotan II nasal spray is an intranasal research format of the synthetic cyclic heptapeptide Melanotan II (MT-II), prepared as an aqueous solution for laboratory delivery studies rather than for injection-based reconstitution. In preclinical research, this format is studied specifically for how the nasal mucosa handles a small, cyclic melanocortin agonist and whether the intranasal route offers a viable non-parenteral pathway for delivering peptides that act on the melanocortin receptor family. This article examines the mechanism of Melanotan II, the rationale behind studying it as a nasal spray, and the mucosal-absorption questions that make the intranasal format scientifically distinct from a reconstituted injectable preparation.
For research use only. Melanotan II and all products described here are intended strictly for laboratory, in-vitro, and preclinical research. They are not for human or veterinary use, are not evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease. Nothing below constitutes dosing guidance or medical advice.
What Melanotan II Is at the Molecular Level
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), an endogenous 13-amino-acid melanocortin. MT-II is a truncated, cyclized heptapeptide — a lactam bridge between residues constrains the molecule into a conformation that resists enzymatic degradation and improves receptor binding relative to native α-MSH. Its molecular weight is roughly 1024 Da, placing it at the small end of the peptide spectrum, which is directly relevant to nasal-delivery research because smaller, conformationally stable molecules are generally more favorable candidates for mucosal absorption.
MT-II is a broadly non-selective melanocortin receptor agonist. Research characterizes it as an agonist at MC1R, MC3R, MC4R, and MC5R. This receptor promiscuity is the reason MT-II is used as a mechanistic probe across multiple melanocortin pathways in preclinical models. For a deeper treatment of the compound itself, see our Melanotan II Research Guide: MC Agonist, and for the wider receptor landscape, the Melanocortin System: Receptor Mechanism Guide.
Receptor Pathways Studied
- MC1R — expressed on melanocytes; downstream cAMP signaling and its role in melanogenesis are the classical focus of MT-II research.
- MC3R / MC4R — central melanocortin receptors investigated in energy-balance and appetite-signaling research models.
- MC5R — associated with exocrine and sebaceous pathway studies.
Why Study Melanotan II as a Nasal Spray?
The intranasal route is of research interest because the nasal cavity presents a thin, highly vascularized mucosal epithelium with a large absorptive surface area and direct access to systemic circulation that bypasses first-pass hepatic metabolism. For peptides — which are poorly absorbed orally because gastric and intestinal proteases degrade them — non-oral, non-injection routes are an active field. The nasal-spray format lets researchers ask a specific question: can a cyclic melanocortin agonist cross the nasal epithelium in a reproducible, measurable way?
Melanotan II is a comparatively strong candidate for this line of inquiry. Its low molecular weight, cyclic stability, and amphipathic character all sit within the property window that intranasal-delivery research generally considers favorable. Our Intranasal Peptide Delivery: Mechanism Guide covers the underlying transport routes in detail; the summary below applies them to MT-II specifically.
Nasal Absorption Routes Under Investigation
| Route | Mechanism | Relevance to MT-II |
|---|---|---|
| Paracellular | Passage between epithelial cells through tight junctions | Primary hypothesized route for a small, hydrophilic cyclic peptide |
| Transcellular | Passive or carrier-mediated transport across cell membranes | Limited by MT-II's charged residues; studied as a secondary pathway |
| Olfactory / trigeminal | Direct nose-to-CNS transport bypassing the blood–brain barrier | Of interest given MT-II's central MC3R/MC4R activity in research models |
Intranasal Format vs. Reconstituted Injectable
The most important distinction in a laboratory setting is that the nasal spray is a ready-buffered aqueous solution optimized for mucosal contact, whereas a reconstituted preparation is lyophilized peptide dissolved in bacteriostatic water for a different delivery model. The two formats answer different research questions and are not interchangeable in study design. Our comparison piece, Nasal Spray vs Reconstituted Peptide Formats, breaks this down further.
- Bioavailability profile — intranasal peptide absorption is typically lower and more variable than parenteral routes; quantifying that gap is often the point of the study.
- Formulation variables — pH, tonicity, viscosity, and mucoadhesive or permeation-enhancer excipients materially affect nasal uptake and are controlled experimental factors.
- Mucociliary clearance — the nasal cavity clears deposited material within minutes, so residence time is a key measured variable absent from injectable models.
- Enzymatic exposure — nasal aminopeptidases can degrade peptides at the mucosa, another variable that MT-II's cyclic backbone is studied against.
Parallel Melanocortin Nasal Formats
Researchers frequently compare MT-II against its more MC1R-selective linear analog. Our companion article, Melanotan I Nasal Spray: Research Format, examines that comparison — the two compounds share a delivery route but differ in receptor selectivity and stability, making side-by-side nasal studies informative for structure–absorption relationships.
Laboratory Handling of the Nasal Spray Format
The following is laboratory handling guidance for research preparations only. It is not a usage protocol.
- Storage — keep the sealed spray refrigerated at 2–8 °C and protected from light. Peptides in solution are less stable than lyophilized powder, so solution-format products have a shorter working stability window.
- Temperature excursions — allow refrigerated solution to equilibrate before priming to avoid condensation and inconsistent spray actuation.
- Integrity checks — inspect for cloudiness, particulates, or discoloration before any measurement; these indicate degradation or contamination.
- Documentation — record lot number and reference the third-party Certificate of Analysis (COA) for purity confirmation in study records.
Purity and Sourcing for Research
Absorption and receptor-binding data are only as reliable as the compound behind them. NeuroLabs supplies Melanotan II 10mg at ≥99% purity with third-party COA testing and same-day USA shipping, so nasal-delivery and melanocortin-pathway studies start from a characterized, documented reference material. This nasal-format guide sits under our pillar overview, Peptide Nasal Spray Research Formats, which frames how intranasal delivery is studied across the peptide catalog.
Key Takeaways
- Melanotan II is a small, cyclic, non-selective melanocortin agonist (MC1R–MC5R) well-suited as a nasal-delivery research probe.
- The intranasal format is studied for paracellular and potential nose-to-CNS transport, distinct from injectable reconstituted preparations.
- Mucociliary clearance, nasal peptidases, and formulation variables are the central experimental factors in this research.
- Rigorous storage and COA documentation underpin reproducible melanocortin data — strictly for laboratory research use only.